Leveraging technological advances to facilitate new ways of engaging patients and integrating non-invasive technology into a liver disease program not only serves to improve individual outcomes and reduce costs but also strengthens the financial performance of health systems and provider organizations that include this approach to testing.
At a time when America’s hospitals and physician groups face lost revenues due to the COVID-19 pandemic, there is a pressing need for reducing costs while
Read More
Echosens
Non-Invasive Technology for Measuring & Monitoring Liver Fat
As part of the growing awareness about chronic disease, it’s important to understand the relationship between nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and diabetes. As a common complication of Type 2 diabetes and obesity, NAFLD can be overlooked comorbidity.
Diabetes is one of the leading causes of disability and death in the United States. One in 10 Americans have diabetes – more than 30 million people – and
Read More
Technology Behind Innovative Screening for Non-alcoholic Fatty Liver Disease
The American Liver Foundation estimates that over 30 percent of the U.S. population has some degree of non-alcoholic fatty liver disease (NAFLD), the most common type of liver disease in the Western world. This can impact other factors of overall health, given the link between NAFLD and diabetes, obesity, insulin resistance, and other metabolic risk factors.One of the key issues in NAFLD patients is the differentiation of NASH from simple steatosis and identification of advanced hepatic
Read More
